Keyphrases
Immune Checkpoint Inhibitors
100%
Anti-PD-1
100%
Real-life Setting
100%
Advanced Urothelial Cancer
100%
Metastatic Urothelial Carcinoma
83%
Progressive Disease
33%
Partial Response
33%
Mixed Response
33%
Complete Response
33%
Stable Disease
33%
Chi-square
16%
Logistic Regression
16%
Multivariable
16%
Clinical Parameters
16%
Potential Gains
16%
Standard of Care
16%
Overall Survival
16%
Kaplan-Meier
16%
Chart Review
16%
Absolute Neutrophil Count
16%
Single Center
16%
Fisher's Exact Test
16%
Log-rank Test
16%
Treatment Line
16%
Metastasis Sites
16%
Predictive Biomarker
16%
Median Overall Survival
16%
Frequent Monitoring
16%
Biomarker Monitoring
16%
Medicine and Dentistry
Immune Checkpoint Inhibitor
100%
Urothelial Cancer
100%
Transitional Cell Carcinoma
83%
Progressive Disease
33%
Overall Survival
33%
Diseases
33%
Biological Marker
16%
Logistic Regression Analysis
16%
Metastatic Carcinoma
16%
Fisher Exact Test
16%
Absolute Neutrophil Count
16%
Log Rank Test
16%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Immune Checkpoint Inhibitor
100%
Transitional Cell Carcinoma
83%
Diseases
66%
Overall Survival
33%
Biological Marker
16%
Biochemistry, Genetics and Molecular Biology
Immune Checkpoints
100%
Overall Survival
33%
Absolute Neutrophil Count
16%
Immunology and Microbiology
Overall Survival
100%
Neutrophil Count
50%